Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study.

Autor:	Sadat Larijani M; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran., Sorouri R; IPI Directorate, Pasteur Institute of Iran, Tehran 1316943551, Iran., Eybpoosh S; Quality Control Department, Production and research Complex, Pasteur Institute of Iran, Tehran-Karaj 3159915111, Iran., Doroud D; Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran 1316943551, Iran., Moradi L; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran., Ahmadinezhad M; Quality Control Department, Production and research Complex, Pasteur Institute of Iran, Tehran-Karaj 3159915111, Iran., Bavand A; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran., Ashrafian F; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran., Tajmehrabi Namini P; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran., Zali M; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran., Ramezani A; Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
Jazyk:	angličtina
Zdroj:	Pathogens and disease [Pathog Dis] 2023 Jan 17; Vol. 81.
DOI:	10.1093/femspd/ftad010
Abstrakt:	Early reports on coronavirus disease 2019 (COVID-19) vaccines presented the short-term adverse events (AEs). This follow-up study investigated a standard regimen based on protein subunit vaccines, PastoCovac and PastoCovac Plus, and the combinational vaccine regimens including AstraZeneca/PastoCovac Plus and Sinopharm/PastoCovac Plus. The participants were followed up to 6 months post the booster shot. All the AEs were collected through in-depth interviews using a valid researcher-made questionnaire and were evaluated regarding the association with the vaccines. Of the 509 individuals, 6.2% of the combinational vaccine participants had late AEs, of whom 3.3% suffered from cutaneous manifestations, followed by 1.1% arthralgia complaints, 1.1% with neurologic disorders, 0.3% ocular problems and 0.3% metabolic complications, with no significant difference between the vaccine regimens. For the standard regimen, 2% of the individuals experienced late AEs as (1%), neurological disorders (0.3%), metabolic problems (0.3%) and involvement of joints (0.3%). Notably, 75% of the AEs were persistent up to the end of the study. A low number of late AEs were captured in 18 months as 12 improbable, 5 unclassifiable, 4 possible and 3 probable associated AEs with the vaccine regimens. The benefits of COVID-19 vaccination far exceed the potential risks and late AEs seem to be uncommon. (© The Author(s) 2023. Published by Oxford University Press on behalf of FEMS.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu